Aurinia Pharmaceuticals (AUPH) Tops Q2 EPS by 10c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.08), $0.10 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $41.49 million versus the consensus estimate of $37.9 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Oppenheimer Starts Teva Pharma (TEVA) at Outperform
• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'